Meclizine
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Meclizine: From Motion Sickness/Vertigo to Allergic Urticaria
One-Sentence Summary
Meclizine is a first-generation (piperazine-class) H1-antihistamine known primarily for treating motion sickness and vertigo. The TxGNN model predicts it may be effective for Allergic Urticaria, but this prediction is currently supported only by class-level pharmacological reasoning — no clinical trials or published literature directly test meclizine in this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded (no TFDA license on file); per known pharmacology, meclizine is used for motion sickness/vertigo (antiemetic, vestibular suppressant) |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.67% |
| Evidence Level | L4 (mechanism/class-effect reasoning, no direct trials or literature) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for meclizine is not currently available in this evidence pack. Based on known pharmacological information, meclizine belongs to the first-generation piperazine-class H1-antihistamines; its efficacy in motion sickness and vertigo (via antiemetic and vestibular-suppressant activity) is well established, and mechanistically it may be applicable to allergic urticaria.
The rationale rests on H1-receptor antagonism: antihistamines of this class are standard first-line therapy for urticaria. Since meclizine shares this receptor-level mechanism with other H1-antihistamines used to treat urticaria, a class-effect argument supports the plausibility of the prediction.
However, this is a drug-class-level inference rather than evidence specific to meclizine itself. No clinical trials or publications currently link meclizine to allergic urticaria treatment, so the mechanistic argument alone should not be treated as clinical proof of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA warnings/contraindications data is a blocking data gap for this candidate — see Conclusion below.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by drug-class mechanistic reasoning (H1-antihistamine → urticaria), with no meclizine-specific clinical trials or literature evidence. The drug is also not currently marketed in Taiwan (0 NDAs), and critical safety data (TFDA package insert warnings/contraindications) is missing, which blocks any safety pre-assessment.
To proceed, the following is needed:
- TFDA package insert data (warnings, contraindications) — blocking gap, required before any safety review
- Confirmed mechanism of action (MOA) from DrugBank or primary literature
- Direct clinical trial or literature evidence for meclizine specifically in allergic/cold urticaria
- Drug-drug interaction (DDI) profile, currently not found
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.